In Reply: Acquired drug-resistance because of pharmacokinetic variability in a young child with tuberculosis

Pediatric Infectious Disease Journal

Volumn 33, Issue 11, 2014, Pages 1205-1206

  Garcia Prats, Anthony J ^a   Donald, Peter R ^a   Schaaf, H Simon ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

DRUG EXPOSURE; DRUG MONITORING; HUMAN; LETTER; PERSONALIZED MEDICINE; PHARMACOKINETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUBERCULOSIS; WORLD HEALTH ORGANIZATION; DRUG EFFECTS; MALE; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84925936492     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000404     Document Type: Letter

References (3)

1. Kearns GL, Abdel-Rahman SM, Alander S W, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.
2. Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother. 2011;55:5560-5567.
3. World Health Organization. Rapid Advice: Treatment of Tuberculosis in Children 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241500449-eng.pdf. Accessed April 18, 2012.